New cancer drug combo seeks to shrink advanced tumors

NCT ID NCT07158918

Recruiting now Disease control Sponsor: ABL Bio, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing the safety and effectiveness of a new drug called ABL103 when combined with an existing immunotherapy (pembrolizumab), with or without chemotherapy. It's for adults with advanced or spreading solid tumors that have continued to grow despite standard treatments. The study aims to find the right dose and see if this combination can help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, 05505, South Korea
PASO Medical
NOT_YET_RECRUITING

Frankston, Victoria, 3199, Australia
Samsung Medical Center
NOT_YET_RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
UH Cleveland Medical Center
NOT_YET_RECRUITING

Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS